319 related articles for article (PubMed ID: 18782590)
21. General Molecular Strategy for Development of Arenavirus Live-Attenuated Vaccines.
Iwasaki M; Ngo N; Cubitt B; Teijaro JR; de la Torre JC
J Virol; 2015 Dec; 89(23):12166-77. PubMed ID: 26401045
[TBL] [Abstract][Full Text] [Related]
22. Development of peptide-conjugated morpholino oligomers as pan-arenavirus inhibitors.
Neuman BW; Bederka LH; Stein DA; Ting JP; Moulton HM; Buchmeier MJ
Antimicrob Agents Chemother; 2011 Oct; 55(10):4631-8. PubMed ID: 21825302
[TBL] [Abstract][Full Text] [Related]
23. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies.
Emonet SE; Urata S; de la Torre JC
Virology; 2011 Mar; 411(2):416-25. PubMed ID: 21324503
[TBL] [Abstract][Full Text] [Related]
24. Generation of recombinant arenavirus for vaccine development in FDA-approved Vero cells.
Cheng BY; Ortiz-Riaño E; de la Torre JC; Martínez-Sobrido L
J Vis Exp; 2013 Aug; (78):. PubMed ID: 23928556
[TBL] [Abstract][Full Text] [Related]
25. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening.
Rathbun JY; Droniou ME; Damoiseaux R; Haworth KG; Henley JE; Exline CM; Choe H; Cannon PM
J Virol; 2015 Aug; 89(16):8428-43. PubMed ID: 26041296
[TBL] [Abstract][Full Text] [Related]
26. Sodium hydrogen exchangers contribute to arenavirus cell entry.
Iwasaki M; Ngo N; de la Torre JC
J Virol; 2014 Jan; 88(1):643-54. PubMed ID: 24173224
[TBL] [Abstract][Full Text] [Related]
27. Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions.
Moreno H; Grande-Pérez A; Domingo E; Martín V
Viruses; 2012 Nov; 4(11):2786-805. PubMed ID: 23202505
[TBL] [Abstract][Full Text] [Related]
28. Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform.
Welch SR; Spengler JR; Genzer SC; Chatterjee P; Flint M; Bergeron É; Montgomery JM; Nichol ST; Albariño CG; Spiropoulou CF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34203149
[TBL] [Abstract][Full Text] [Related]
29. Current drug discovery strategies against arenavirus infections.
Pasquato A; Burri DJ; Kunz S
Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1297-309. PubMed ID: 23241187
[TBL] [Abstract][Full Text] [Related]
30. Envelope glycoprotein of arenaviruses.
Burri DJ; da Palma JR; Kunz S; Pasquato A
Viruses; 2012 Oct; 4(10):2162-81. PubMed ID: 23202458
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs.
Herring S; Oda JM; Wagoner J; Kirchmeier D; O'Connor A; Nelson EA; Huang Q; Liang Y; DeWald LE; Johansen LM; Glass PJ; Olinger GG; Ianevski A; Aittokallio T; Paine MF; Fink SL; White JM; Polyak SJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468464
[TBL] [Abstract][Full Text] [Related]
32. Multifunctional nature of the arenavirus RING finger protein Z.
Fehling SK; Lennartz F; Strecker T
Viruses; 2012 Nov; 4(11):2973-3011. PubMed ID: 23202512
[TBL] [Abstract][Full Text] [Related]
33. Treatment of arenavirus infections: from basic studies to the challenge of antiviral therapy.
Damonte EB; Coto CE
Adv Virus Res; 2002; 58():125-55. PubMed ID: 12205778
[No Abstract] [Full Text] [Related]
34. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials.
Olschläger S; Flatz L
PLoS Pathog; 2013; 9(4):e1003212. PubMed ID: 23592977
[TBL] [Abstract][Full Text] [Related]
35. Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.
Botten J; Sidney J; Mothé BR; Peters B; Sette A; Kotturi MF
Microbiol Mol Biol Rev; 2010 Jun; 74(2):157-70. PubMed ID: 20508245
[TBL] [Abstract][Full Text] [Related]
36. The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors.
Kim YJ; Cubitt B; Chen E; Hull MV; Chatterjee AK; Cai Y; Kuhn JH; de la Torre JC
Antiviral Res; 2019 Sep; 169():104558. PubMed ID: 31302150
[TBL] [Abstract][Full Text] [Related]
37. Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.
Brisse ME; Ly H
Front Immunol; 2019; 10():372. PubMed ID: 30918506
[TBL] [Abstract][Full Text] [Related]
38. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses.
Lee AM; Rojek JM; Spiropoulou CF; Gundersen AT; Jin W; Shaginian A; York J; Nunberg JH; Boger DL; Oldstone MB; Kunz S
J Biol Chem; 2008 Jul; 283(27):18734-42. PubMed ID: 18474596
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of arenavirus hemorrhagic fevers.
Moraz ML; Kunz S
Expert Rev Anti Infect Ther; 2011 Jan; 9(1):49-59. PubMed ID: 21171877
[TBL] [Abstract][Full Text] [Related]
40. A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans.
Botten J; Whitton JL; Barrowman P; Sidney J; Whitmire JK; Alexander J; Kotturi MF; Sette A; Buchmeier MJ
J Virol; 2010 Oct; 84(19):9947-56. PubMed ID: 20668086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
